Qihan Biotechnology scores $67m

Qihan Biotechnology Co, a Chinese provider of genome editing technology to cell therapies and organ transplantation, has raised $67 million in financing.

Qihan Biotechnology Co, a Chinese provider of genome editing technology to cell therapies and organ transplantation, has raised $67 million in financing. The investors included Lilly Asia Ventures, Matrix Partners China, Sequoia and CMB International.

Source: Press Release